Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Kiniksa Pharmaceuticals International has received a consensus recommendation of "Buy" from six covering brokerages, with an average price target of $41.17.
• The company reported earnings of $0.23 EPS, surpassing analysts' expectations, with a net margin of 0.90% for the recent quarter.
• Significant share transactions occurred, including insider selling, with over 679,686 shares sold by company insiders valued at about $21.27 million in the last quarter.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has earned an average recommendation of "Buy" from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have covered the stock in the last year is $41.1667.

Several research firms have weighed in on KNSA. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Finally, Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 17,000 shares of the company's stock in a transaction on Monday, August 4th. The shares were sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the sale, the chief accounting officer owned 33,041 shares in the company, valued at approximately $1,068,876.35. The trade was a 33.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John F. Paolini sold 29,325 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total transaction of $954,528.75. Following the completion of the transaction, the insider directly owned 57,403 shares of the company's stock, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 674,849 shares of company stock worth $21,144,188. 53.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after buying an additional 532 shares during the last quarter. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. US Bancorp DE bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth approximately $33,000. Quantbot Technologies LP bought a new position in shares of Kiniksa Pharmaceuticals International during the second quarter worth approximately $43,000. Finally, Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth approximately $41,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Up 0.5%

Shares of Kiniksa Pharmaceuticals International stock traded up $0.17 during midday trading on Thursday, hitting $33.75. The company's stock had a trading volume of 356,168 shares, compared to its average volume of 705,288. The firm has a market capitalization of $2.50 billion, a P/E ratio of 843.96 and a beta of 0.14. The stock has a 50-day simple moving average of $29.78 and a 200-day simple moving average of $25.53. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $34.55.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.